Home›Screener›FUSN›Profile
D
40/100

Fusion Pharmaceuticals

FUSNOncology
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Fusion Pharmaceuticals (FUSN) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 3 Phase 2[1].

No Form 4 insider filings for FUSN were recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. SEC EDGAR (2026-04-11) ↗
🔬
Clinical Trials
3
NCT05219500Metastatic Castration Resistant Prostate Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06402331Metastatic Castration-resistant Prostate Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06909825Metastatic Castration-resistant Prostate Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Oncology)
NUVBNuvation Bio
B
LBPHLongboard Pharmaceuticals
B
SNDXSyndax Pharmaceuticals
C
KURAKura Oncology, Inc.
C
INCYIncyte Corporation
C
Data Provenance
clinical trial3 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR